Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jonsson Comprehensive Cancer Center
With
AstraZeneca
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of utilizing a new Federal Drug Administration (FDA)-cleared radiofrequency tag for localization of non-palpable breast lesions and provide preliminary data for a larger study.
OUTLINE:
Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
After completion of study, patients are followed up within 2 weeks.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to give written informed consent to participate in the study
Able to read and write English
Patients with breast lesions that are non-palpable that require surgical removal
Lesions and/or clip targetable with image guidance
You may not be if
Multicentric breast cancer
Stage IV breast cancer
Pregnant or lactating females
Clareo Health | Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery
